false
0001840563
0001840563
2024-05-03
2024-05-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 3, 2024
Elevai Labs Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
|
001-41875 |
|
85-1399981 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
c/o 120 Newport Center Drive, Ste. 250
Newport Beach, CA |
|
92660 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: 866-794-4940
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value |
|
ELAB |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material
Definitive Agreement.
On May 3, 2024, the Board
of Directors (the “Board”) of Elevai Labs Inc. (the “Company”) approved the Company entering into a one-year consulting
agreement (the “Agreement”) with Santorio Biomedical, LLC (the “Consultant”) for the services of Mr. Deniel Mero,
Director of Santorio Biomedical, LLC, whereby the Consultant will cause Mr. Mero to perform his services as outlined in Exhibit
A to the Agreement and Consultant will be compensated on behalf of Mr. Mero by the Company in connection with his performance
of such services. The Consultant will cause Mr. Mero, as an independently contracted consultant to primarily provide services
to the Company’s wholly owned subsidiary Elevai Biosciences Inc., an Elevai Labs company which include but are not limited to, (i)
discover, assess, and introduce biotechnology opportunities to the Company; (ii) advise the Board regarding certain strategic matters,
including development of biotechnology pipeline assets, recruiting a contract research organization (CRO), assisting in efforts to recruit
potential directors and team members to build the biotechnology division and forming a scientific advisory board; and (iii) to perform
services for subsidiaries of the Company as may be necessary.
The Consultant will
receive a $180,000 fee per year payable in monthly installments. In addition, the Consultant was granted 2,450,000 shares of
restricted common stock (the “Shares”) payable in four installments over the course of ten months, which Mr. Mero will be
deemed to beneficially own indirectly. Within one year after the final and fourth grant of the Shares, the Company has agreed to register
the Shares under a registration statement to be filed with the United States Securities and Exchange Commission.
The foregoing description
of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy
of which is filed herewith as Exhibit 10.1 and is incorporated in its entirety herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May
9, 2024
Elevai Labs, Inc. |
|
|
|
|
By: |
/s/ Jordan R. Plews |
|
Name: |
Jordan R. Plews |
|
Title: |
Chief Executive Officer, President and Director |
|
2
Exhibit
10.1
CONSULTING AGREEMENT
This Consulting
Agreement (this “Agreement”), effective as of May 3, 2024 (“Effective Date”), is entered into by
and between Elevai Labs Inc., a Delaware corporation (“Company”), and Santorio Biomedical, LLC, a
Delaware limited liability company (“Consultant”).
For good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the parties agree as follows.
1. Consulting
Relationship. During the term of this Agreement, Consultant will perform for Company the consulting services as described on Exhibit
A (the “Services”). Consultant shall perform the Services in a diligent and professional matter, and in compliance
with all applicable laws and regulations. Without limiting the foregoing, Company acknowledges that the relationship with Consultant is
not exclusive, and that Consultant may perform services for other parties that are the same or similar to the Services provided for Company
hereunder, provided that Consultant at all times abides by the Confidentiality Agreement (as defined below) and the terms and provisions
of this Agreement intended to survive the expiration or termination thereof.
2. Fees.
As consideration for the Services performed by Consultant and other obligations, Company shall pay Consultant the amounts specified in
Exhibit B at the times specified therein.
3. Expenses.
Consultant will be responsible for all expenses incurred while performing the Services unless Consultant receives the prior written approval
of the Company to reimburse a particular expense. Without limiting the right of Company to deny approval, as a condition to receipt of
reimbursement, Consultant shall be required to submit to Company reasonable evidence that the amount involved was both reasonable and
necessary to the Services provided under this Agreement.
4.
Term and Termination.
(a) Subject
to section 4(b), this Agreement shall commence on the Effective Date and continue in force until May 3, 2025 (the “Expiration
Date”), unless earlier terminated in accordance with this Section 4 or extended by mutual written agreement of both parties
(as the case may be, the “Term”).
(b) Either
party may terminate this Agreement prior to the Expiration Date for any or no reason, by providing at least thirty (30) days prior written
notice to the other party.
(c) If
(i) Company breaches any of its obligations pursuant to this Agreement or (ii) Consultant breaches any of its obligations pursuant to
this Agreement including, but not limited to, Consultant’s obligations under the Confidential Information and Invention Assignment
Agreement between Company and Consultant, the form of which is attached hereto as Exhibit C (the “Confidentiality Agreement”),
then the non-breaching party may terminate this Agreement by providing written notice to the breaching party setting forth the basis for
the termination. Termination for breach shall become effective upon the non-breaching party’s delivery of notice provided that the
breaching party fails to cure within five (5) business days thereafter.
(d) If
this Agreement is terminated for any or no reason, the Company shall nevertheless issue the Shares listed in Exhibit B as specified
therein and use commercially reasonable efforts to register the Shares.
5. Independent
Contractor. Consultant’s relationship with Company will be that of an independent contractor and not that of an employee
or agent. Unless authorized by the Company in writing in advance, Consultant shall provide its own office space, equipment, and supplies
necessary to perform the Services.
6. Provision
of Services. Consultant is responsible for determining the method, details and means of performing the Services.
7. No
Authority to Bind Company. Neither Consultant nor any of its personnel has the authority to enter into any contract that binds
Company or creates any obligations on the part of Company.
8. No
Benefits. Neither Consultant nor any of its personnel is eligible for any Company employee benefits. Further, to the extent Consultant
or any of its personnel otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, Consultant
on behalf of itself and its personnel hereby expressly declines to participate in such Company employee benefits.
9. Taxes.
Consultant shall have full responsibility for applicable withholding taxes for all compensation paid to Consultant under this Agreement,
and for compliance with all applicable labor and employment requirements with respect to Consultant’s self- employment, franchise
tax, worker’s compensation insurance coverage requirements and U.S. immigration visa requirements.
10. Confidential
Information and Invention Assignment Agreement. Consultant shall sign, or has signed, the Confidentiality Agreement, which shall
be effective as of the Effective Date. Consultant shall ensure that each of its personnel performing the Services on behalf of Consultant
shall have entered into confidentiality agreement with Consultant obligating such personnel to abide by the provisions of this Agreement.
11.
Representations and Warranties
(a) Consultant
represents and warrants that: (i) Neither Consultant nor any of its personnel is under any pre-existing obligation in conflict or in any
way inconsistent with the provisions of this Agreement; (ii) Consultant’s performance of this Agreement will not breach any agreement
to keep in confidence proprietary information acquired by Consultant in confidence or in trust prior to commencement of this Agreement.
(iii) to Consultant’s knowledge, Consultant has all rights, licenses and permissions required for it to perform the Services and
receive the compensation hereunder.
(b) Company
represents and warrants that: (i) it has the full right, power, and authority to enter into this Agreement and to perform its obligations
hereunder; and (ii) the execution of this Agreement by its representative whose signature is set forth at the end of this Agreement has
been duly authorized by all necessary corporate action.
12. MUTUAL
LIMITATION OF LIABILITY. IN NO EVENT WILL COMPANY OR CONSULTANT BE LIABLE FOR ANY SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES
OF ANY KIND IN CONNECTION WITH THIS AGREEMENT, EVEN IF COMPANY OR CONSULTANT HAS BEEN INFORMED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.
13.
Indemnification.
(a) By
Company. The Company shall defend, indemnify, and hold harmless the Consultant and its affiliates and their officers, directors, employees,
agents, successors, and assigns (“Consultant Indemnitees”), to the fullest extent permitted by law, from and
against all losses, liabilities, deficiencies, actions (including derivative shareholder actions), judgments, interest, awards, penalties,
fines, costs, or expenses of whatever kind (including reasonable attorneys’ fees) arising out of or resulting from the Company’s
use or reliance on Consultant’s Services or advice or information provided by Consultant, except to the extent of any bad faith
or intentional or willful misconduct of any Consultant Indemnitees. In no event shall the aggregate liability of the Company connection
with any and all claims arising out of this Agreement exceed the aggregate amount of cash compensation paid by the Company to Consultant
pursuant to this Agreement.
(b) By
Consultant. Consultant shall indemnify, defend and hold harmless the Company and its affiliates and their officers, directors, employees,
agents, successors, and assigns (“Company Indemnitees”) from and against all losses, liabilities, deficiencies,
actions (including derivative shareholder actions), judgments, interest, awards, penalties, fines, costs, or expenses of whatever kind
(including reasonable attorneys’ fees) arising out of or resulting from any bad faith or intentional or willful misconduct of any
Consultant Indemnitee, or any breach of or failure to comply with this Agreement on the part of any Company Indemnitee. In no event shall
the aggregate liability of Consultant in connection with any and all claims arising out of this Agreement, the Services or any deliverables
provided by Consultant exceed the aggregate amount of cash compensation paid by the Company to Consultant pursuant to this Agreement.
14.
Miscellaneous.
(a) Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect
to the principles of conflict of law provisions thereof. Any dispute or controversy arising under or in connection with this Agreement
shalt be settled exclusively by arbitration in Orange County, California in accordance with the rules of the American Arbitration Association
(“AAA”) then in effect. Arbitration will take place before a single experienced arbitrator licensed to practice law in California.
Any judgment rendered by the arbitrator as above provided shall be final and binding on the parties hereto for all purposes and may be
entered in any court having jurisdiction. In any arbitration pursuant to this Section 14(a), each party shall be responsible for the fees
and expenses of its own attorney and witnesses, and the fees and expenses of the arbitrator shall be divided equally between Company and
the Consultant. Consultant agrees that the cost provisions of this Section 14(a) are fair and not unconscionable.
(b) Entire
Agreement; Other Agreements. This Agreement, together with the Confidentiality Agreement, sets forth the entire agreement and
understanding of the parties relating to the subject matter herein and therein. For the avoidance of doubt, this Agreement supersedes
all prior or contemporaneous discussions, understandings and agreements (original or amended), whether oral or written, between them relating
to the subject matter hereof.
(c) Amendments
and Waivers. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective
unless in writing signed by the parties to this Agreement. No delay or failure to require performance of any provision of this Agreement
shall constitute a waiver of that provision as to that or any other instance.
(d) Successors
and Assigns. Consultant may not assign, whether voluntarily or by operation of law, any of its rights and obligations under this
Agreement, except with the prior written consent of Company. Subject to the foregoing, this Agreement will be binding upon and inure to
the benefit of the respective successors, assigns, heirs, executors, administrators and legal representatives of the parties.
(e) Notices.
Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed sufficient
when delivered personally, by overnight courier or sent by email, addressed to the party to be notified at such party’s address
as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature page, at
the most recent address set forth in Company’s books and records.
(f) Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such
provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision,
then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision
were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms.
(g) Construction.
This Agreement is the result of negotiations between and has been reviewed by each of the parties and their respective counsel, if any;
accordingly, this Agreement shall be deemed to be the product of both parties, and no ambiguity shall be construed in favor of or against
either party.
(h) Signatures.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original,
and all of which together shall constitute one and the same agreement. Signatures received by facsimile, PDF file or other electronic
format (including DocuSign) shall be deemed to be original signatures.
[Signature Page Follows]
IN WITNESS WHEREOF, the parties have executed this Agreement
and made it effective as of the Effective Date.
|
COMPANY: |
|
|
|
|
ELEVAI LABS INC. |
|
|
|
|
By: |
/s/ Graydon Bensler |
|
Name: |
Graydon Bensler |
|
Title: |
CFO and Director |
|
Address: |
120 Newport Center Drive, Newport Beach, CA 92660, USA |
|
CONSULTANT: |
|
|
|
|
SANTORIO BIOMEDICAL, LLC |
|
|
|
|
By: |
/s/ Deniel Mero |
|
Name: |
Deniel Mero |
|
Title: |
Director |
|
Address: |
99 Wall St, Suite 1925, New York, NY, 10005 |
|
Business Tax ID: |
37-2118799 |
EXHIBIT
A
DESCRIPTION OF SERVICES
| (1) | Discover, assess, and introduce biotechnology opportunities
to the Company. |
| (2) | Advise the Board of Directors regarding certain strategic
matters, including development of biotechnology pipeline assets, recruiting a contract research organization (CRO), assisting in efforts
to recruit potential directors and team members to build the biotechnology division and forming a scientific advisory board. |
| (3) | Provide advice and support for investor relations and capital
markets awareness by building marketing materials and generating a plan to circuit investment conferences with Company. |
| (4) | Strategize with Company IP lawyers to compose a patent portfolio. |
| (5) | The foregoing Services may be performed in the Consultant’s
(or Consultant’s personnel) capacity as an officer of the Company, subject to terms and conditions to be agreed by the parties
in writing. |
EXHIBIT
B
COMPENSATION
This Exhibit B sets forth the compensation
to be paid in exchange for the performance of the Services specified in Exhibit A.
Consultant will be compensated with a
monthly cash fee of $15,000 for Consultant’s fractional time of approximately 60%. In addition, the Company shall promptly (but
no later than 5 business days from the issuance dates below (each an “Issuance Date”) take all required steps to issue shares
of common stock of Elevai Labs Inc., par value $0.0001 per share (the “Shares”):
| · | Effective Date: 612,500 Shares |
| · | August 1, 2024: 612,500 Shares |
| · | November 1, 2024: 612,500 Shares |
| · | February 2, 2025: 612,500 Shares |
If this Agreement is terminated for any
or no reason, Company shall issue the full number of Shares listed above immediately and use commercially reasonable efforts to register
the Shares. For clarity, if this Agreement is terminated before the full 2,450,000 Shares have been issued to Consultant, Company will
issue the full 2,450,000 Shares to Consultant immediately upon termination of Agreement; provided, however, that (notwithstanding
the foregoing) Shares not previously issued or issuable by the Company hereunder shall no longer be issuable by the Company hereunder
if, prior to the Issuance Date thereof as set forth above, the Consultant (or its personnel performing Services): (i) fundamentally or
materially fails to perform the Services after being provided with written notice of such failure and a 30 day period to cure; (ii) stands
convicted by a court of any fraud, theft, embezzlement or other criminal act of a similar nature; (iii) engages in an act of intentional
and material dishonesty or fraud; or (iv) materially breaches of any material term of the Confidentiality Agreement.
Further Shares
Consultant agrees that it, together with
its Affiliates, will in no event acquire or own any shares of common stock of Elevai Labs Inc., par value $0.0001 per share, other than
the Shares issued to Consultant hereunder without the prior written consent of Company.
For purposes of the foregoing “Affiliate”
means, with respect to Consultant, any other person or entity which directly or indirectly controls, is controlled by, or is under common
control with, Consultant. For the purposes of this definition, a person or entity shall be regarded as in control of or common control
with Consultant if it or Deniel Mero owns, or directly or indirectly controls, more than fifty percent (50%) of the voting stock or other
ownership interest such person or entity, or if Consultant or Deniel Mero directly or indirectly possesses the power to direct or cause
the direction of the management and policies of the other person or entity by any means whatsoever.
Registration Rights
The
Company agrees that it will use its commercially reasonable efforts to file with the Securities and Exchange Commission (the
“SEC”) (at Company’s sole cost and expense), within one year after the final issuance of Shares hereunder
(the “One-Year Period”), a registration statement (the “Registration Statement”) registering the
resale of such Shares issued to Consultant hereunder (“Registrable Securities”), and the Company shall use its
commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the filing
thereof; provided, however, that: (i) if the Company shall during the One-Year Period file any registration statement
for any other primary or secondary sale of shares of its common stock with the SEC, then such Registrable Securities shall be
included therein (and such registration statement shall constitute the “Registration Statement” hereunder); and (ii) the
Company’s obligations to include the Registrable Securities in the Registration Statement are contingent upon Consultant
furnishing in writing to the Company such information regarding Consultant, the securities of Company held by Consultant and its
affiliates and the intended method of disposition of the Registrable Securities as shall be reasonably requested by the Company to
effect the registration of the Registrable Securities, and shall execute such documents in connection with such registration as the
Company may reasonably request that are customary of a selling stockholder in similar situations, and provided that the
Company shall be entitled to postpone and suspend the effectiveness or use of the Registration Statement during any customary
blackout or similar period or as otherwise permitted by Consultant.
EXHIBIT C
CONFIDENTIAL INFORMATION AND INVENTION
ASSIGNMENT AGREEMENT
IN WITNESS WHEREOF, the parties have executed this Agreement
as of the Effective Date.
|
COMPANY: |
|
|
|
|
ELEVAI LABS INC. |
|
|
|
|
By: |
/s/ Graydon Bensler |
|
|
(Signature) |
|
Name: |
Graydon Bensler |
|
Title: |
CFO and Director |
|
Address: |
120 Newport Center Drive, Newport Beach, CA 92660 USA |
|
CONSULTANT: |
|
|
|
|
Santorio Biomedical, LLC |
|
|
|
|
By: |
/s/ Deniel Mero |
|
Name: |
Deniel Mero |
|
Title: |
Director |
|
Address: |
99 Wall St, Suite 1925, New York, NY, 10005 |
EXHIBIT A-1
LIST OF PRIOR
INVENTIONS EXCLUDED UNDER SECTION 4(a)
v3.24.1.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Jul 2023 to Jul 2024